The Complete GLP-1 Tracker & Medication Knowledge Base

Foundayo (orforglipron) is Eli Lilly's once-daily oral GLP-1 medication for chronic weight management, approved April 1, 2026, and the first small-molecule, non-peptide GLP-1 receptor agonist, meaning it can be taken at any time of day without food or water restrictions, unlike the Ozempic and Wegovy tablets.

Semaglutide is a GLP-1 receptor agonist available as a once-weekly injection or once-daily tablet, marketed under two brand names with distinct approved uses: Ozempic® for type 2 diabetes and Wegovy® for chronic weight management. Depending on the brand, it's also approved to reduce cardiovascular risk in adults with established cardiovascular disease.

Ozempic® (semaglutide) is a once-weekly GLP-1 receptor agonist prescribed to improve blood sugar control in adults with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.

Tirzepatide for chronic weight management.

Trulicity® (dulaglutide) is a once-weekly GLP-1 receptor agonist approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors.

Adlyxin® (lixisenatide) is a once-daily, mealtime GLP-1 receptor agonist approved as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Unlike weekly GLP-1 medications, Adlyxin is timed to a meal and taken once daily within the hour before the first meal of the day.

Cagrilintide is an investigational long-acting amylin analog developed by Novo Nordisk. It is not FDA-approved as a standalone medication. Its main development path is CagriSema, a fixed-dose combination with semaglutide, which was submitted to the FDA for approval in December 2025 and is under review in 2026.

Retatrutide is an investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly. It is not FDA-approved and not available by prescription as of July 2026. Phase 3 trial results have shown up to 28.3% average weight loss at 80 weeks -- among the highest reported for any obesity medication in development -- with an NDA filing expected in late 2026 and potential approval as early as 2027-2028.

Saxenda® (liraglutide) is a once-daily GLP-1 receptor agonist approved for chronic weight management in eligible adults and adolescents when used alongside a reduced-calorie diet and increased physical activity. It contains the active ingredient liraglutide and is intended to be used as part of a comprehensive weight management plan.

Wegovy® (semaglutide) is a GLP-1 receptor agonist, available as a once-weekly injection or once-daily tablet, approved for chronic weight management in adults and adolescents aged 12 and older with obesity or overweight. It is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

Rybelsus® (semaglutide) was an oral GLP-1 receptor agonist approved for improving blood sugar control in adults with type 2 diabetes. As of May 2026, Rybelsus has been discontinued in the US and replaced by a new, higher-bioavailability oral semaglutide tablet marketed under the Ozempic® brand name.

Byetta® (exenatide) was a twice-daily GLP-1 receptor agonist approved for type 2 diabetes and was the first-ever approved GLP-1 medication. Byetta was discontinued by AstraZeneca in October 2024, and the FDA formally withdrew its approval in September 2025. A generic exenatide product remains available.

Compounded semaglutide is a non-FDA-approved version of semaglutide prepared by compounding pharmacies. As of 2026, its legal availability is sharply restricted following the FDA's resolution of the semaglutide shortage in February 2025 — it is generally only available through narrow, documented clinical-need exceptions.

Tirzepatide is a once-weekly injectable medication that activates both GLP-1 and GIP receptors — a dual mechanism that distinguishes it from single-target GLP-1 drugs like semaglutide. It's marketed under two brand names: Mounjaro® for type 2 diabetes and Zepbound® for chronic weight management and obstructive sleep apnea.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood sugar control in adults with type 2 diabetes and, under certain brand names, to support chronic weight management. It is the active ingredient in Victoza® and Saxenda®. Liraglutide works by increasing insulin release when blood glucose levels are elevated, slowing stomach emptying, and reducing appetite.

Mounjaro® (tirzepatide) is a once-weekly dual GLP-1/GIP receptor agonist approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It also carries a cardiovascular indication, with 2025 label updates showing reduced risk of cardiovascular death or worsening heart failure in adults with heart failure with preserved ejection fraction (HFpEF).

Victoza® (liraglutide) is a once-daily GLP-1 receptor agonist prescribed to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease.

Bydureon BCise® (exenatide extended-release) was a once-weekly GLP-1 receptor agonist approved for type 2 diabetes. Bydureon BCise was discontinued by AstraZeneca in October 2024. A generic exenatide product remains available.

Compounded tirzepatide is a non-FDA-approved version of tirzepatide prepared by compounding pharmacies. Its legal status has shifted repeatedly since 2024 and, unlike semaglutide, some reports indicate tirzepatide returned to a shortage-adjacent status in 2025 — making current availability genuinely unsettled and worth verifying directly with the FDA before assuming either way.